Davidsson P - Search Results

1

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V. Parnetti L, et al. Among authors: davidsson p. Neurol Sci. 2002 Sep;23 Suppl 2:S95-6. doi: 10.1007/s100720200086. Neurol Sci. 2002. PMID: 12548360 Clinical Trial.

2

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.

Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Davidsson P, et al. Neurosci Lett. 2001 Mar 16;300(3):157-60. doi: 10.1016/s0304-3940(01)01586-5. Neurosci Lett. 2001. PMID: 11226635 Clinical Trial.

3

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Andreasen N, et al. Among authors: davidsson p. Acta Neurol Scand Suppl. 2003;179:47-51. doi: 10.1034/j.1600-0404.107.s179.9.x. Acta Neurol Scand Suppl. 2003. PMID: 12603251 Clinical Trial.

4

Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients.

Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Möller HJ, Hampel H, Davidsson P, Blennow K. Olsson A, et al. Among authors: davidsson p. Exp Neurol. 2003 Sep;183(1):74-80. doi: 10.1016/s0014-4886(03)00027-x. Exp Neurol. 2003. PMID: 12957490 Clinical Trial.

5

Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia.

Wallin A, Sjögren M, Blennow K, Davidsson P. Wallin A, et al. Among authors: davidsson p. Dement Geriatr Cogn Disord. 2003;16(4):200-7. doi: 10.1159/000072803. Dement Geriatr Cogn Disord. 2003. PMID: 14512714

6

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Puchades M, et al. Among authors: davidsson p. Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):140-6. doi: 10.1016/j.molbrainres.2003.08.005. Brain Res Mol Brain Res. 2003. PMID: 14559363

7

Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms.

Nilselid AM, Davidsson P, Nägga K, Andreasen N, Fredman P, Blennow K. Nilselid AM, et al. Among authors: davidsson p. Neurochem Int. 2006 Jun;48(8):718-28. doi: 10.1016/j.neuint.2005.12.005. Epub 2006 Feb 21. Neurochem Int. 2006. PMID: 16490286

8

A new procedure for detecting brain-specific proteins in cerebrospinal fluid.

Davidsson P, Ekman R, Blennow K. Davidsson P, et al. J Neural Transm (Vienna). 1997;104(6-7):711-20. doi: 10.1007/BF01291888. J Neural Transm (Vienna). 1997. PMID: 9444570

9

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Andreasen N, et al. Among authors: davidsson p. Neurosci Lett. 1999 Sep 24;273(1):5-8. doi: 10.1016/s0304-3940(99)00617-5. Neurosci Lett. 1999. PMID: 10505638 Clinical Trial.

10

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD.

Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Sjögren M, et al. Among authors: davidsson p. Neurology. 2000 May 23;54(10):1960-4. doi: 10.1212/wnl.54.10.1960. Neurology. 2000. PMID: 10822437

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters